Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; none of the 62 sources its claims cite is checked for support yet.
Abstract
The importance of MCL-1 in leukemogenesis has prompted development of MCL-1 antagonists e.g., S63845, MIK665. However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via the ubiquitin proteasome system. Here, we investigated mechanisms by which kinase inhibitors with Src inhibitory activity e.g., bosutinib (SKI-606) might circumvent this phenomenon. MCL-1 antagonist/SKI-606 co-administration synergistically induced apoptosis in diverse AML cell lines. Consistently, Src or MCL-1 knockdown with shRNA markedly sensitized cells to MCL-1 inhibitors or SKI-606 respectively, while ectopic MCL-1 expression significantly diminished apoptosis. Mechanistically, MCL-1 antagonist exposure induced MCL-1 up-regulation, an event blocked by Src inhibitors or Src shRNA knock-down. MCL-1 down-regulation was associated with diminished transcription and increased K48-linked degradative ubiquitination. Enhanced cell death depended functionally upon down-regulation of phosphorylated STAT3 (Tyr705/Ser727) and cytoprotective downstream targets c-Myc and BCL-xL, as well as BAX/BAK activation, and NOXA induction. Importantly, the Src/MCL-1 inhibitor regimen robustly killed primary AML cells, including primitive progenitors, but spared normal hematopoietic CD34+ cells and human cardiomyocytes. Notably, the regimen significantly improved survival in an MV4-11 cell xenograft model, while reducing tumor burden in two patient-derived xenograft (PDX) AML models and increased survival in a third. These findings argue that Src inhibitors such as SKI-606 potentiate MCL-1 antagonist anti-leukemic activity in vitro and in vivo by blocking MCL-1 antagonist-mediated cytoprotective MCL-1 accumulation by promoting degradative ubiquitination, disrupting STAT-3-mediated transcription, and inducing NOXA-mediated MCL-1 degradation. They also suggest that this strategy may improve MCL-1 antagonist efficacy in AML and potentially other malignancies.
Overview
CoChat Summary
TL;DR
Src inhibitors such as bosutinib/SKI-606 block MCL-1 antagonist-induced MCL-1 accumulation and synergistically kill AML cells in vitro and in vivo. The regimen also kills primary AML blasts, including primitive progenitors, while sparing normal CD34+ cells and cardiomyocytes, and improves survival in xenograft/PDX models.
Key findings
- S63845 (20 nM) or SKI-606 (2 μM) alone minimally affected U937 viability, but together induced apoptosis with PARP/caspase-3 cleavage and γH2A.X; synergy was seen by Median Dose Effect analysis (CI < 1.0) across U937, MV4-11, MOLM-13, and OCI-AML3 cells, and with MIK665 or dasatinib combinations.
- MCL-1 antagonists increased MCL-1 expression, which SKI-606 blocked; MCL-1 knockdown sensitized cells to SKI-606, Src knockdown sensitized cells to S63845/MIK665, and ectopic MCL-1 protected cells. Mechanistically, combination treatment increased K48-linked MCL-1 ubiquitination, was blocked by MG132, induced NOXA, dephosphorylated STAT3 (Tyr705/Ser727), reduced MCL-1 transcription and c-MYC/BCL-xL, and required BAX/BAK for cell death.
- In primary AML samples, S63845 or MIK665 plus SKI-606 synergistically induced apoptosis in CD34+ blasts and primitive CD34+CD38−CD123+ cells, but did not increase death in normal CD34+ cells (14 S63845 samples, 10 MIK665 samples) or AC16 human cardiomyocytes.
- In vivo, S63845/SKI-606 reduced U937 flank tumor volume/weight, reduced MV4-11 systemic tumor burden, and improved survival versus single agents (log-rank P = 0.0452 vs S63845 and P = 0.0038 vs SKI-606); PDX models showed reduced hCD45+ cells in peripheral blood, bone marrow, and spleen, with increased survival in a third PDX model and no weight loss.
Methods
- In vitro studies used human AML cell lines U937, MV4-11, MOLM-13, and OCI-AML3; primary AML blasts; normal cord blood CD34+ cells; and AC16 human ventricular cardiomyocytes. Treatments included S63845, MIK665, SKI-606/bosutinib, and dasatinib, with assays including 7-AAD/Annexin V flow cytometry, CellTiter-Glo viability, western blotting, immunoprecipitation, qRT-PCR, ImageStream, shRNA knockdown, CRISPR knockout, and ectopic expression.
- In vivo studies used NSG or NSG-SGM3 mice with U937 flank tumors, luciferase-labeled MV4-11 systemic/flank models, and AML patient-derived xenografts; S63845 was dosed at 25, 20, or 15 mg/kg and SKI-606 at 150 or 60 mg/kg, with monitoring of tumor volume, IVIS signal, hCD45+ cells, survival, and body weight.
- Statistical analysis used means ± SD from at least three independent experiments, Student t test or one-way ANOVA with Tukey-Kramer comparisons, median dose-effect analysis with Calcusyn for synergy (CI < 1.0), and Kaplan-Meier/log-rank tests for survival.
Limitations
- The paper states that the mechanism by which Src interruption promotes degradative MCL-1 ubiquitination remains to be defined; the relative functional contribution of proteomic, phosphorylation-array, and metabolomic changes compared with MCL-1 down-regulation remains to be determined; and whether the lack of toxicity in vitro can be extrapolated to patients remains to be determined.
- Evident from the text: efficacy is shown in cell lines and immunocompromised mouse/PDX models, not in a clinical trial, and many mechanistic confirmations rely on Supplementary figures rather than fully presented main-text data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 The S63845/SKI-606 regimen exhibits significant in vivo activity. a–e NOD/SCID-γ NSG mice (5 mice/group) were inoculated in the right flank with 1 × 106 U937 cells. Treatment was initiated after 8 days. S63845 (25 mg/kg, twice a week, I.P.) ± SKI-606 (150 mg/kg, 5 days weekly, p.o.) were administrated weekly for 2 weeks. a Tumor size was monitored every other day. Mean tumor volume was calculated using the formula (1/2 × [length × width2]). b, c At day 21, tumors were harvested and weighed. d Mouse body weights were monitored every other day throughout the treatment period. P > 0.05. e Immunoblotting analysis was then performed to monitor expression of PARP, cleaved caspase-3 and γH2A.X. β-actin was assayed to ensure equivalent loading and transfer. f–i Mice (10 mice/group) were inoculated via tail vein with 5 × 106 MV4-11 cells stably expressing luciferase. After signals were visible (e.g, 13 days after injection of tumor cells), S63845 (15 mg/kg, twice a week for two weeks, then adjusted to one time weekly for three weeks, I.P.) ± SKI-606 (150 mg/kg, 5 days weekly, p.o.) were administrated for 5 weeks. Control animals were administered equal volumes of vehicle. f Tumor burden was monitored every week after subcutaneous (sub-Q) injection with 150 mg/kg luciferin using the IVIS 200 imaging system. g Quantification of the luminescent signal. Data represents the means ± SD performed on all mice for each group. h Kaplan–Meier survival plot (P = 0.0452 and 0.0038 for the combination vs S63845 or SKI-606 alone, respectively, by log-rank test). i Mouse body weights during treatment (P > 0.05). CF, cleavage fragment. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001](https://figures.cochat.ai/paper-figures/9ce4c7d3be584f23bf0f825103370e93/src-inhibition-potentiates-mcl-1-antagonist-activity-in-acute-myeloid-leukemia-figure-6.jpg)


Verification
Claims the paper makes
0 Valid · 1 Not valid · 47 Not checked · 90 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Annexin V staining demonstrated a marked increase in apoptosis (Fig. 1c), which was synergistic over a range of concentrations by Median Dose Effect analysis (Fig. 1d).”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > Interactions between MCL-1 and Src inhibitors in AML cells
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Identical results were obtained with the MCL-1 antagonist MIK665 (Fig. 1e–h, Supplementary Fig. S1b).”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > Interactions between MCL-1 and Src inhibitors in AML cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MCL-1 antagonist/SKI-606 co-administration synergistically induced apoptosis in diverse AML cell lines.”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
In the paper
“Additionally, STRING analysis indicated that the down-regulated proteins PPP2R5E and PPP2CA have significant connections to BCL2 signaling,39 demonstrating high-confidence interactions (score = 0.700) (Supplementary Fig. S18d).”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > Proteomic analysis of MCL-1/Src inhibitor synergism
What the sources say
- Not checked yetcites [39] Deng, X., Gao, F. & May, W. S. Protein phosphatase 2A inactivates Bcl2’s antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 113, 422–428 (2009). source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Synergistic actions of combined treatment was observed by comparing changes in metabolite intensity for statistically significant differences between treatment and control groups.”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > Metabolomics profiling reveals the impact of combination treatment on cell metabolism
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 138 claims and to verify the 62 references still open.
- It may state two separate claims as one. 39
- The quote only partly states this claim. 15
- Probably not a substantial claim. 33
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > The MCL-1/SFK inhibitor regimen markedly inhibits leukemic cell expansion in an AML patient-derived xenograft (PDX) model
“i Kaplan–Meier survival plot. Mice (10 mice/group) were inoculated with 5 × 106 primary blasts #03 via tail vein.”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Materials and methods > Patient-derived xenograft (PDX) models of AML
“(2) For survival studies, mice (9 mice/group) were inoculated with 5 × 106 primary AML blasts #03 via the tail vein.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > The MCL-1 inhibitor/SKI-606 regimen induces apoptosis in a STAT3-dependent manner
“b Cells were stained with p-STAT3 (Y705), p-STAT3 (Y727) and DAPI”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > The MCL-1 inhibitor/SKI-606 regimen induces apoptosis in a STAT3-dependent manner
“a Western blot analysis of p-STAT3 (Y705), p-STAT3 (S727), MCL-1, c-MYC, BCL-XL in U937 cells treated with 20 nM S63845 ± 2 µM SKI-606 for 16 h.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Discussion
“proteomic analysis revealed down-regulation of PPP25RE and PP2CA”
§ Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia > Results > Proteomic analysis of MCL-1/Src inhibitor synergism
“the 23 down-regulated proteins specific to the S63 + SKI treatment group identified 4 proteins (GSK3β, GYG1, PPP2CA, and PPP2R5E)”
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
Acute myeloid leukemia: Epidemiology and etiology
Deschler, B., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.22233 · Cited by 646
Khwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A., Fairlie, W. D., Izon, D. J., Zuber, J., Rappaport, A. R., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 423
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
Cell Death in the Origin and Treatment of Cancer
Strasser, A., & Vaux, D. L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.014 · Cited by 370
Cited by
Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies
Mukherjee, N., Sheetz, J., & Shellman, Y. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209859 · Cited by 29
Huang, B., Yulin, Y., Liu, J., Zhang, B., & Lin, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533007 · Cited by 6
Maher, K. R., Murray, G. F., Ho, T. N., & Grant, S. (2025) · Journal of Cellular Signaling · doi:10.33696/signaling.6.133 · Cited by 3
Self-citationJianati, R., Chen, H., Yang, X., Yan, L., Guo, Y., Fan, C., Hao, X., Zhu, G., & Shi, Z. (2025) · Oncology Reports · doi:10.3892/or.2025.9005 · Cited by 3
Ureshino, H., Ueshima, T., Yamaguchi, T., Takashima, M., Sanuki, Y., & Ichinohe, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-98534-7 · Cited by 3
Metadata
- Authors
- Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., Mauro, A. G., Salloum, F. N., Hazlehurst, L., Sdrimas, K., Moore, Z., Zhou, L., Ginder, G. D., & Grant, S.
- Affiliations
- Virginia Commonwealth University (US)
- West Virginia University (US)
- Corresponding author
- Grant, Steven
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-02-10
- Volume
- 10
- Issue
- 1
- Pages
- 50-50
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11808118
- OpenAlex
- W4407284284
- Semantic Scholar
- f3ee9a4a27e24dabf77074b238544fcc158f019e
- Cited by
- 15
- References
- 58
- Citations by year
- 2026: 6 · 2025: 9
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Veterans Affairs (IK6 BX006315, I01BX000200)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL151243)
- National Cancer Institute (R01CA205607, UM1CA186644, P30CA016059)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- acute myeloid leukemia, Mcl-1, Src kinase inhibitor, bosutinib, ubiquitin-proteasome degradation, STAT3 signaling, Noxa, apoptosis, c-Myc, Bcl-xL, combination therapy, patient-derived xenografts, cardiotoxicity
- MeSH terms
- Aniline Compounds, Animals, Humans, Nitriles, Pyrimidines, Quinolines, Thiophenes, Leukemia, Myeloid, Acute, Apoptosis, src-Family Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, STAT3 Transcription Factor, Mice, Ubiquitination, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia. https://app.cochat.ai/papers/10.1038/s41392-025-02125-x
- The paper
- Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., Mauro, A. G., Salloum, F. N., Hazlehurst, L., Sdrimas, K., Moore, Z., Zhou, L., Ginder, G. D., & Grant, S. (2025). Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02125-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.